


Supplemental Table S1. Oligonucleotides used for site-directed mutagenesis.

Mutation	Oligonucleotides (5' to 3')
Pto(L68I/K69R)	F: GATGGAGCAAAGGTCGCGATCCGTAGGCGTACACCTGAGTCC R: GGACTCAGGTGTACGCCTACGGATCGCGACCTTTGCTCCATC
Pto(D182E)	F: CCCTTTCTTGGATATTCCGAATTCAGTAATTTTTGGCAC R: GTGCCAAAAATTACTGAATTCGGAATATCCAAGAAAGGG
Pto(T199A)	F: CAAACCCATCTTAGCGCAGTAGTGAAAGGAAC R: GTTCCTTTCACTACTGCGCTAAGATGGGTTTG



Supplemental Fig. S1. Chemical structure of PP1 analogs.

PP1: 1-*tert*-Butyl-3-*p*-tolyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

Bn-PP1: 3-Benzyl-1-*tert*-butyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

1NA-PP1: 1-*tert*-Butyl-3-naphthalen-1-yl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

2NA-PP1: 1-*tert*-Butyl-3-naphthalen-2-yl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

1NM-PP1: 1-*tert*-Butyl-3-naphthalen-1-ylmethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

2NM-PP1: 1-*tert*-Butyl-3-naphthalen-2-ylmethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.


Ac-PP1: 3-Acenaphthen-5-yl-1-*tert*-butyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

3MB-PP1: 1-*tert*-Butyl-3-(3-methylbenzyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.

aMB-PP1: 1-*tert*-butyl-3-(1-phenylethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine.

3BrB-PP1: 3-(3-bromobenzyl)-1-*tert*-butyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-amine.

23dMB-PP1: 1-*tert*-Butyl-3-(2,3-dimethylbenzyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-ylamine.



Supplemental Fig. S2. Treatment of *N. benthamiana* leaves expressing Pto^{as} mutants with 3MB-PP1 does not elicit an AvrPto-independent HR.

N. benthamiana leaves were infiltrated with *Agrobacterium* strains for the expression of the indicated Pto forms in the absence of AvrPto, or expression of Pto and AvrPto, as positive control. Twenty hours later, infiltrated areas were treated with 3MB-PP1 or DMSO as control, and monitored during 4 days for the appearance of the HR.